

June 2, 2015



POXEL to Present New Imeglimin Clinical Results at the ADA 75th Scientific Sessions

--Poster Presentation on Full Data Analysis of Imeglimin Phase 2b--

--Webcast and Conference Call to Discuss New Clinical Data and Provide Corporate Update--

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, today announced that the Company will present full data analysis of a Phase 2b trial for their drug candidate Imeglimin at the upcoming American Diabetes Association (ADA) 75th Scientific Sessions in Boston, MA, on Saturday, June 6 and Sunday, June 7.

"Corroborating the top line results released in December 2014, Poxel is excited to have the opportunity to provide details on the remarkable efficacy and safety/tolerability results of our Imeglimin Phase 2b trial at the prestigious ADA meeting. Presenting at this well-attended conference enables the recognition of Imeglimin's true novelty and promise for diabetic patients," commented Thomas Kuhn, CEO of Poxel.

Poxel is actively progressing Imeglimin development worldwide. The Company's management will host a conference call and webcast to provide a complete view of this development and to discuss Imeglimin's clinical profile on Tuesday, June 9, 2015 at 12:00 p.m. EDT.

ADA Presentation

Abstract: Dose-Ranging Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes (# 1169-P)

Guided Audio Poster Tour: Saturday, June 6, 11:30 - 12:30 PM, Session 3-CT-PT02 - Novel Oral Agents, Boston Convention Center, Hall B - Poster Hall

General Poster Presentation: Sunday, June 7, 12:00 - 2:00 PM, Boston Convention Center, Hall B - Poster Hall

Conference Call and Webcast

The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the conference ID 58212381.

US Toll-Free: (877) 293-6124
International: +1 (678) 562-4238
Local Dial-In Numbers:
France, Paris: 0170807153
Germany, Berlin: 030726167368
Japan, Tokyo: 357674011
Netherlands, Amsterdam: 0207075535
Switzerland, Zurich: 0445801733
United Kingdom, London: 02031070289

An audio webcast of the conference call can be accessed by logging onto <http://edge.media-server.com/m/p/ysxfoukt> or on the Poxel website at www.poxel.com. A replay of the webcast will be available on Poxel's website shortly after the conclusion of the call and will be archived there for 30 days following the call.

About Poxel SA

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed phase 2 development in the US and EU and has entered clinical development in Japanese subjects. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20150601006902/en/>

NewCap

Investor relations / Media - France

Florent Alba/Nicolas Mérieau, + 33 1 44 71 98 55

poxel@newcap.fr

or

Investor relations / Media - EU/US

MacDougall Biomedical Communications

Gretchen Schweitzer or Anca Alexandru, + 49 89 2424 3494

aalexandru@macbiocom.com

Source: Poxel SA